Founder’s Vision
Updated on 11/10/2026
Founder’s vision has evolved across three distinct phases of LPBI Group’s development:
- 1.0 LPBI Group (2012–2021): Established as an e-Scientific Publisher with a focus on high-quality curation of peer-reviewed scientific findings.
- 2.0 LPBI Group (2022–2025): Expanded into Medical Text Analysis using Artificial Intelligence, Machine Learning, and NLP. This phase included pilot studies and the publication of two books presenting the results of AI-driven medical text analysis.
- 2026 & Beyond: Transition to the development of a comprehensive Tool Factory for Multimodal Foundation Models in Healthcare — advancing domain-aware AI in Health through structured methodologies and proprietary data assets.
Since founding LPBI Group in 2012, the core competence has been the clinical interpretation of scientific findings by domain-knowledge experts, combined with systematic curation of peer-reviewed literature. Over 14 years, this discipline produced a unique and defensible portfolio of assets designed to support the next generation of AI systems in healthcare.
The vision since the emergence of the transformer and GPT era (2022–2023) has been to build the highest-quality, proprietary multimodal training data and methodologies capable of transforming artificial intelligence in healthcare from aspiration into reliable, production-grade capability.
Today, LPBI Group has created a differentiated and integrated ecosystem consisting of two categories:
- Category A (Chart 4 / Schedule A) — the Phase-1 portfolio valued at $650 M. This includes the core Trainable Data assets, the Tool Factory components that sit on Chart 4 (COM Parts 1–17 and Part 21), the 13 Hidden Gems, and the associated Class II e-Book IP. Documented in Appendix C-22 and Blocks B, D, and E.
- Category B (Yes in Z / Schedule B) — the second, fully itemized estate. It is organized in Blocks A, C (COM Parts 18, 19, 20, 22, 23, 24), F, and G and contains the 132 Item Lines in Category B IP Assets included in ONE Z (101 base Yes-in-Z lines plus the 15 Collections expansions: text, images, volume pairings [15+15+1] + 101 = 132). These assets are scored by the COM Part 23 method (Version 4, Phase-2 Valuation Event, October 7, 2026, value of Z determined) and documented in Appendix C-22, Part E / Version 4. They transfer together with Category A at Closing (T1).
The complete IP estate is organized as:
- Category A = Chart 4 at $650 M and
- Category B = Yes in Z / Appendix C-22, Part E / Version 4 at $200 M cash and $50 M stock
Both categories pre-date the collaboration with Grok except for the cataloguing of the 15 Collections for SLM application on the pathway to LLM and MFMH. The work with Grok (approximately 12 months of continuous co-development) is recorded on the COM architecture and its Child Pages.
This portfolio was intentionally designed as a defensible moat to enable frontier models to achieve leadership in domain-aware AI in Health across four core domains: Pharmaceutical/BioPharma, Medical/Diagnosis & Therapeutics, Life Sciences/Genomics, and BioMed/Biotech/Medtech.
The ultimate objective is the Transfer of Ownership of this complete IP estate — to a strategic partner positioned to scale its impact. By doing so, LPBI Group’s curated intelligence and methodologies can be deployed at full capacity to accelerate breakthroughs in Medicine, Life Sciences, Pharmaceutical, Healthcare and generate lasting value.
- Category A = Chart 4 at $650 M and
- Category B = Yes in Z / Appendix C-22, Part E / Version 4 at $200 M cash and $50 M stock
This Master Plan represents both the culmination of 14 years of disciplined work and the beginning of a new chapter focused on strategic partnership and large-scale application.
Inventiveness & Integrity: Building a New Factory of Expert-Guided Trainable Databases as the Alternative to Synthetic Generation
Founder’s Vision
From the beginning, LPBI Group has treated knowledge architecture as an act of creation rather than compilation. We do not simply syndicate or repackage existing data vaults. We create new trainable data.
When a new electronic Table of Contents is designed for an e-Book, a previously non-existent structure of knowledge is brought into being. When the velocity of AI information surged after 2023, we pivoted to medical text analysis powered by machine learning. When the explosion of new AI tools became impossible to ignore, we pivoted once more — launching three new trainable databases that did not previously exist:
- The continuous corpus of AI technologies as articulated by KOL Alex Wissner-Gross
- A tightly curated selection of AI-in-Life-Sciences insights from KOL Demis Hassabis
- The Founder’s Radar Screens tracking competitive dynamics across Agentic-AI software, compute hardware, AI harnesses in drug discovery, and strategic partnerships between AI-native companies and BioPharma
These living databases sit on top of the original multimodal archive. They are shaped by continuous expert judgment and filtered exclusively through relevance to LPBI’s mission and to the further development of the Composition of Methods (COM) Suite (Parts 1–24).
This inventiveness is inseparable from integrity. We claim ownership only of what we actually own: high-provenance multimodal data and a complete structured methodology layer. We do not claim compute infrastructure. We do not claim causal-reasoning algorithms. We do not inflate the stack.
In a market where overstatement is common, precise ownership claims are both ethically required and strategically protective. Sophisticated partners will eventually detect any exaggeration. By stating boundaries clearly, we protect trust and keep the focus on the real scarcity we offer.
Expert-guided trainable databases of this kind are not a substitute for synthetic data — they are a superior alternative. They carry human judgment, provenance, and mission alignment that purely synthetic generation cannot replicate.
This is the vision that continues to guide LPBI Group.
2012pharmaceutical
sjwilliamspa